Drug · CHEMBL417
EPIRUBICIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EPIRUBICIN. Drugs and targets, record CHEMBL417. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL417
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 4'-epi-adriamycin, Epiadriamycin, Epidoxorubicin, Epirubicina, Epirubicine, Farmorubicin, NSC-256942
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases70
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Phase 3 | ClinicalTrials.gov | 200 | 200 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| triple-negative breast carcinoma | Phase 3 | ClinicalTrials.gov | 25 | 25 | https://conductscience.org/library/drugs?q=MONDO_0005494 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 21 | 21 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| hepatocellular carcinoma | Phase 3 | ClinicalTrials.gov | 13 | 13 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| gastric adenocarcinoma | Phase 3 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=MONDO_0005036 |
| gastroesophageal junction adenocarcinoma | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0003219 |
| diffuse large B-cell lymphoma | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| esophageal adenocarcinoma | Phase 3 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0005028 |
| cancer | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0004992 |
| inflammatory breast carcinoma | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0006804 |
1 to 10 of 70Source Open Targets
See all 70 diseasesTrials372
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Phase 3 | 4,804 | 2018-01-05 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00087178 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | Phase 3 | 2,722 | 2022-08-11 | epirubicin | Its name | ClinicalTrials.gov |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | Phase 3 | 2,199 | 2024-08-21 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00129935 | EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer | Phase 3 | 1,384 | 2019-10-25 | epirubicin | Its name | ClinicalTrials.gov |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy | Phase 2 | 442 | 2026-01-12 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00381706 | Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | Phase 2 | 245 | 2017-03-15 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00976989 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | Phase 2 | 225 | 2016-06-20 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00432172 | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | Phase 2 | 189 | 2019-07-17 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00454636 | A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | Phase 2 | 158 | 2016-08-19 | epirubicin | Its name | ClinicalTrials.gov |
| NCT00193206 | Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | Phase 2 | 123 | 2012-11-30 | epirubicin | Its name | ClinicalTrials.gov |
1 to 10 of 372
See all 372 trialsComparisons in its trials41
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 | 26 of 1,337 | 2,688 | NCT00087178 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 58 of 1,098 | 72 of 1,101 | 2,199 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: Number of Participants With Adverse Events (AE) | 1,074 of 1,084 | 1,090 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events | 173 of 1,084 | 280 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| Arm A: EC-T vs Arm B: ET-X: Number of Participants With Disease-free Survival (DFS) Event | 127 of 669 | 170 of 715 | 1,384 | NCT00129935 | Trial comparisons |
| Arm A: EC-T vs Arm B: ET-X: deaths from any cause | 70 of 669 | 83 of 715 | 1,384 | NCT00129935 | Trial comparisons |
| Arm A: EC-T vs Arm B: ET-X: Number of Participants With Overall Survival (OS) Event | 70 of 669 | 83 of 715 | 1,384 | NCT00129935 | Trial comparisons |
| Arm A: EC-T vs Arm B: ET-X: serious adverse events | 111 of 669 | 138 of 715 | 1,384 | NCT00129935 | Trial comparisons |
1 to 10 of 41
See all 41 comparisons in its trialsPapers from its trials325
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL417
GET https://conductscience.org/api/drugs/v1/CHEMBL417/diseases?page=2